They included 15 patients with CRCLM and 7 patients with HCC and measured several angiogenic factors, including non-classical factors such as interleukin-8, at baseline and during follow-up until 120 days after treatment. This evidence concerns the gene CXCL8 and hepatocellular carcinoma.